Chapman University

Chapman University Digital Commons
Psychology Faculty Articles and Research

Psychology

10-2012

Randomized Clinical Trial of Cognitive Behavioral
Therapy (CBT) versus Acceptance and
Commitment Therapy (ACT) for Mixed Anxiety
Disorders
Joanna Arch
University of Colorado, Boulder

Georg Eifert
Chapman University, geifert@chapman.edu

Carolyn Davies
University of California - Los Angeles

Jennifer C. Plumb Vilardaga
University of Nevada, Reno

Raphael D. Rose
University of California - Los Angeles

Follow this and additional works at: http://digitalcommons.chapman.edu/psychology_articles
See next page for additional authors

Part of the Cognitive Psychology Commons, Counseling Psychology Commons, Experimental
Analysis of Behavior Commons, Other Psychiatry and Psychology Commons, and the Other
Psychology Commons
Recommended Citation
Arch, J. J., Eifert, G. H., Davies, C., Plumb, C., Rose, R. D., & Craske, M. G. (2012). Randomized clinical trial of cognitive behavioral
therapy (CBT) versus acceptance and commitment therapy (ACT) for mixed anxiety disorders. Journal of Consulting and Clinical
Psychology, 80(5), 750–765. http://doi.org/10.1037/a0028310

This Article is brought to you for free and open access by the Psychology at Chapman University Digital Commons. It has been accepted for inclusion
in Psychology Faculty Articles and Research by an authorized administrator of Chapman University Digital Commons. For more information, please
contact laughtin@chapman.edu.

Randomized Clinical Trial of Cognitive Behavioral Therapy (CBT) versus
Acceptance and Commitment Therapy (ACT) for Mixed Anxiety
Disorders
Comments

This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Journal of Consulting
and Clinical Psychology, volume 80, issue 5, in 2012 following peer review. The definitive publisherauthenticated version is available online at DOI: 10.1037/a0028310.
This article may not exactly replicate the final version published in the APA journal. It is not the copy of
record.
Copyright

American Psychological Association
Authors

Joanna Arch, Georg Eifert, Carolyn Davies, Jennifer C. Plumb Vilardaga, Raphael D. Rose, and Michael G.
Craske

This article is available at Chapman University Digital Commons: http://digitalcommons.chapman.edu/psychology_articles/61

HHS Public Access
Author manuscript
Author Manuscript

J Consult Clin Psychol. Author manuscript; available in PMC 2016 January 19.
Published in final edited form as:
J Consult Clin Psychol. 2012 October ; 80(5): 750–765. doi:10.1037/a0028310.

Randomized clinical trial of cognitive behavioral therapy (CBT)
versus acceptance and commitment therapy (ACT) for mixed
anxiety disorders
Joanna Arch, Ph.D.,
University of Colorado Boulder

Author Manuscript

Georg H. Eifert, PhD.,
Chapman University
Carolyn Davies,
University of California Los Angeles
Jennifer C. Plumb Vilardaga, M.A.,
University of Nevada Reno
Raphael D. Rose, Ph.D., and
University of California Los Angeles
Michelle G. Craske, Ph.D.
University of California Los Angeles

Author Manuscript

Abstract
Objective—Randomized comparisons of acceptance-based treatments with traditional cognitive
behavioral therapy (CBT) for anxiety disorders are lacking. To address this research gap, we
compared acceptance and commitment therapy (ACT) to CBT for heterogeneous anxiety
disorders.

Author Manuscript

Method—One hundred twenty eight individuals (52% female, mean age = 38, 33% minority)
with one or more DSM-IV anxiety disorders began treatment following randomization to 12
sessions of CBT or ACT; both treatments included behavioral exposure. Assessments at pretreatment, post-treatment, 6-month, and 12-month follow-up measured anxiety specific (principal
disorder Clinical Severity Ratings [CSR], Anxiety Sensitivity Index, Penn State Worry
Questionnaire, Fear Questionnaire avoidance) and non-anxiety specific (Quality of Life Index
[QOLI], Acceptance and Action Questionnaire-16 [AAQ]) outcomes. Treatment adherence and
therapist competency ratings, treatment credibility, and co-occurring mood and anxiety disorders
were investigated.
Results—CBT and ACT improved similarly across all outcomes from pre- to post-treatment.
During follow-up, ACT showed steeper CSR improvements than CBT (p < .05, d = 1.33) and at
12-month follow-up, ACT showed lower CSRs than CBT among completers (p < .05, d = 1.05).
At 12-month follow-up, ACT reported higher AAQ than CBT (p = .08, d = .42; Completers: p < .
05, d = .59) whereas CBT reported higher QOLI than ACT (p < .05, d = .43). Attrition and
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comorbidity improvements were similar, although ACT utilized more non-study psychotherapy at
6-month follow-up. Therapist adherence and competency were good; treatment credibility was
higher in CBT.
Conclusions—Overall improvement was similar between ACT and CBT, indicating that ACT is
a highly viable treatment for anxiety disorders.

INTRODUCTION

Author Manuscript

Several decades ago, the development of behavioral and cognitive behavioral therapy for
anxiety disorders (Barlow & Cerny, 1988; Beck, Emery, & Greenberg, 1985) introduced
time-limited, relatively effective treatments. Numerous randomized clinical trials and metaanalyses (e.g. Butler, Chapman, Forman, & Beck, 2006; Hofmann & Smits, 2008; Norton &
Price, 2007; Tolin, 2010) have demonstrated the effectiveness of CBT for anxiety disorders,
including panic disorder, generalized anxiety disorder, social anxiety disorder, obsessive
compulsive disorder, specific phobia and posttraumatic stress disorder, relative to wait-list
and/or psychological control conditions. As a result of clinical efficacy and ease of
implementation, cognitive behavioral therapy (CBT) has become the dominant empirically
validated treatment for anxiety disorders. However, a significant percentage of individuals
with anxiety disorders do not respond to CBT (e.g., Barlow, Gorman, Shear, & Woods,
2000), relapse following successful treatment (Brown & Barlow, 1995), seek additional
treatment (Brown & Barlow, 1995), or remain vulnerable to developing anxiety and mood
disorders throughout the lifespan (see Craske, 2003). Further, the cognitive model, which
posits that anxiety disorders stem from faulty cognitions and are treated by modifying the
content of these cognitions, has been challenged by insufficient supporting evidence (see
Longmore & Worrell, 2007) and theoretical arguments (see Brewin, 1996)

Author Manuscript
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In attempt to broaden, improve upon, and provide theoretically strong alternatives to
traditional (cognitive model-based) CBT, clinical researchers have shown increasing interest
in mindfulness and acceptance-based treatments for psychopathology. Multiple treatment
approaches have developed out of this exploration, including Acceptance and Commitment
Therapy (ACT; Hayes, Strosahl, & Wilson, 1999), a behavioral therapy that cultivates
mindfulness, acceptance, cognitive defusion (flexible distancing from the literal meaning of
cognitions), and other strategies to increase psychological flexibility and promote behavior
change consistent with personal values. Within ACT, psychological flexibility is defined as
enhancing the capacity to make contact with experience in the present moment, and based
on what is possible in that moment, persisting in or changing behavior in the pursuit of goals
and values (Hayes et al., 1999). Case studies, multiple-baseline treatment studies and a
single randomized clinical trial provide nascent evidence that ACT is an effective treatment
for anxiety disorders, including obsessive compulsive disorder (Twohig et al., 2010), social
anxiety disorder (Dalrymple & Herbert, 2007), panic disorder (Eifert et al., 2009),
generalized anxiety disorder (Wetherell et al., 2011), and posttraumatic stress disorder
(Orsillo & Batten, 2005). However, no randomized clinical trials for anxiety disorders have
yet compared ACT with the gold standard therapy for anxiety disorders, CBT.

J Consult Clin Psychol. Author manuscript; available in PMC 2016 January 19.
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Several studies have compared ACT and CBT within general clinic samples. One
randomized effectiveness trial (n=101) in undiagnosed anxious and depressed patients
(Forman, Herbert, Moitra, Yeomans, & Geller, 2007) compared ACT and CBT1, concluding
that the two treatments were equally effective across symptom outcome measures, but
operated via somewhat different mechanisms. A small (n=28) randomized treatment study
comparing ACT and CBT for undiagnosed “general clinic patients” (Lappalainen et al.,
2007) found that ACT reduced symptoms to a greater degree than CBT and effected
treatment processes at a different rate. In neither study, however, were anxiety disorders
formally diagnosed, significantly limiting the conclusions for the treatment of anxiety
disorders. Roemer, Orsillo and colleagues (2008) developed an acceptance-based treatment
for generalized anxiety disorder (GAD) that integrated several ACT principles, and found it
to be significantly superior to a waitlist control group for the treatment of generalized
anxiety disorder. However, this promising treatment was developed for generalized anxiety
disorder alone and it has not yet been compared to another active treatment.

Author Manuscript

In summary, important work has begun to investigate ACT for anxiety disorders but studies
to date have not compared ACT to the most evidence-based psychotherapy for most anxiety
disorders, CBT. Directly comparing traditional CBT and ACT for anxiety disorders within a
randomized clinical trial bridges a vital gap in the empirical treatment literature, fulfilling
the gold-standard method for investigating the relative efficacy of two treatments for anxiety
disorders (Chambless & Hollon, 1998). Further, it provides an opportunity to compare the
efficacy of treatment packages that contain distinct strategies for dealing with maladaptive
cognitions (change the content of thoughts in CBT vs. change the context by challenging the
need to respond rigidly and literally to cognitions in ACT) and uncomfortable internal
experiences (to master and reduce anxiety in CBT vs. open towards and accept anxiety in
ACT), and that promote different treatment goals (anxiety reduction in CBT vs. living a
valued life in ACT).

Author Manuscript

The current study compares ACT and CBT in a mixed anxiety disorders sample for two
reasons. First, ACT (Hayes et al., 1999) originally was developed for the treatment of
psychopathology in general rather than a specific disorder in particular. The ACT protocol
used in the current study (Eifert & Forsyth, 2005) was designed for application across all of
the anxiety disorders, with the content of values-guided behavioral exercises tailored to
specific anxiety disorders. Second, CBT shares common treatment elements across the
anxiety disorders with variation in content specific to each disorder. We thus designed a
CBT manual that addressed all anxiety disorders via branching mechanisms specific to each
disorder. Our CBT protocol included the same basic treatment elements across all of the
disorders (e.g., psychoeducation, cognitive restructuring, exposure – see Methods) but
tailored the content of these elements to each specific disorder, an approach we have
successfully tested in previous studies (e.g., Craske et al., 2011).
We assessed patients at four longitudinal measurement points, including pre-treatment, posttreatment, 6-month follow up, and 12-month follow up, providing a thorough assessment of

1The study called their approach “cognitive therapy” which they defined as the Beck-based treatment subtype of CBT, see Forman et
al, 2007.
J Consult Clin Psychol. Author manuscript; available in PMC 2016 January 19.
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treatment-related change over time. Due to limited extant data, we did not make specific
predictions regarding whether one treatment would lead to greater reductions in anxiety
disorder-related symptoms than the other treatment. Rather, investigating this question
represented a central study aim. However, given the emphasis in ACT on psychological
flexibility and valued living, we hypothesized that these measures would improve to a
greater degree following ACT than CBT.

METHODS
Participants

Author Manuscript
Author Manuscript

One hundred and forty-three participants (Ps) meeting DSM-IV criteria for a diagnosis of
one or more anxiety disorders, including panic disorder with or without agoraphobia
(PD/A), social anxiety disorder (SAD), specific phobia (SP), obsessive-compulsive disorder
(OCD), or generalized anxiety disorder (GAD)2, were randomized to ACT (n = 65) or CBT
(n = 78). All Ps who began treatment (n = 128) were included in the intent-to-treat (ITT)
sample (n=57 ACT, n=71 CBT). See Table 1 for ITT sample characteristics and Figure 1 for
patient flow. Fifteen of the original 143 Ps, blinded to treatment randomization (unaware if
they had been randomized to ACT or CBT), dropped prior to treatment initiation. Because
pre-treatment attrition gave us no information about treatment preference or response, we
did not analyze those Ps further. Ps who dropped prior to treatment did not differ
significantly from Ps who began treatment on any sociodemographic variable from Table 1
(ps ≥ .20), nor did not differ by blind assignment to ACT vs. CBT (n = 8 each, p = .66). Ps
who dropped treatment showed somewhat higher CSRs (M = 6.07, SD = .96) relative to Ps
who began treatment (M = 5.63, SD = .92), but group differences were small and did not
reach statistical significance p = .08. pη2 = 02. Eleven of the 15 Ps (73%) dropped prior to
completing the pretreatment questionnaire assessment; therefore, we could not determine if
they differed from Ps who initiated treatment on questionnaire measures.
Ps were recruited from the Los Angeles area in response to local flyers, Craig’s List and
local newspaper advertisements, and referrals. The study took place at the Anxiety Disorders
Research Center at the University of California Los Angeles, Department of Psychology.

Author Manuscript

Ps were either medication-free or stabilized on psychotropic medications for a minimum
standard length of time (1 month for benzodiazepines and beta blockers, 3 months for
SSRIs/SNRIs and heterocyclics). Also, Ps were psychotherapy-free or stabilized on
alternative psychotherapies other than cognitive or behavioral therapies, that were not
focused on their anxiety disorder, for at least 6 months prior to study entry3. Ps were
encouraged not to change their non-study medication or alternative psychotherapy during
the course of the study. Exclusion criteria included active suicidal ideation, severe
depression (CSR > 6 on ADIS-IV, see below), or a history of bipolar disorder, psychosis,

2Only 4 Ps met principal diagnosis of posttraumatic stress disorder (PTSD) perhaps because our recruitment materials stated “anxiety
disorders” but not “trauma”, therefore attracting fewer PTSD Ps. Of these, 1 did not begin treatment, 1 dropped treatment, and 2
completed treatment. Due to the very small n for this disorder (3 total PTSD Ps who began treatment, only 1 in ACT), these
participants were excluded from analyses.
3In order to match eligibility requirements between non-study psychotropic medication and non-study psychotherapy, we required a
six month stabilization for each type of non-study treatment.
J Consult Clin Psychol. Author manuscript; available in PMC 2016 January 19.
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mental retardation or organic brain damage. Ps with substance abuse or dependence within
the last 6 months, or with respiratory, cardiovascular, pulmonary, neurological, muscularskeletal diseases or pregnancy were excluded.
Ps received 12 weeks of reduced-cost, sliding scale ($0–100/session) individual treatment,
and received $15–$25 in cash or a gift certificate upon completion of the post-treatment and
each followup assessment. Ps were reimbursed for UCLA parking fees for the assessments
($8–$10). The study was fully approved by the UCLA human subjects protection
committee; full informed consent was obtained from all Ps, including for video- and
audiorecordings.

Author Manuscript

Design—Ps were assessed at pre-treatment (Pre), post-treatment (Post), and at 6 months
(6mFU) and 12 months (12mFU) after Pre. Assessments included a diagnostic interview,
self-report questionnaires, and a 2 to 3 hour laboratory assessment (except at 6mFU)
reported elsewhere. Assessors were blind to treatment condition. Randomization sequences
were produced by www.randomizer.org CBT to ACT. Because fewer Ps were recruited in
the fourth compared to the third quarter, the total number of Ps who began treatment in each
condition was unequal (n = 57 to ACT; n = 71 to CBT). To maximize statistical power for
the main group comparison hypotheses, we did not stratify patients on any variables.

Author Manuscript

Treatments—Following the Pre ADIS-IV and laboratory assessments, Ps were
randomized to treatment condition. Ps received twelve weekly, 1-hour individual CBT or
ACT therapy sessions based on detailed treatment manuals delivered by doctoral student
therapists4. If clients presented with multiple anxiety disorders, treatment focused on the
principal disorder. Following the 12 sessions, therapists conducted follow up phone calls
once per month for 6 months, allowing 20–35 minutes per call to check in and troubleshoot
in a manner consistent with the assigned therapy condition, to enhance long term outcomes
(see Craske et al., 2006).
Therapists

Author Manuscript

Clinical psychology doctoral students at UCLA served as study therapists. The majority of
therapists were relatively naïve to CBT and ACT and inexperienced more generally (i.e., in
their first or second year of treating patients)5. Therapists were assigned to ACT, CBT, or
both (i.e., treated in both CBT and ACT, though never at the same time), depending on the
need for therapists in a particular condition and the availability of training in that condition
(e.g., a multi-day training workshop with an ACT or CBT expert, see below). There were a
total of 39 therapists; eighteen therapists worked exclusively in CBT, 9 worked exclusively
in ACT, and 11 treated both ACT and CBT Ps (but never at the same time). Generally,
therapists treated 1–2 patients at a time and 3–6 therapists worked within each treatment
condition at a time. The mean number of patients treated by CBT-only therapists was M =
1.94, SD = 1.16 (range 1–4) for a total of 35 Ps, by ACT-only therapists was M = 1.89, SD =
1.05 (range 1–4) for a total of 17 Ps, and by therapists who treated in both conditions was M

4See author MGC for a copy of the CBT treatment manual; the ACT manual is published (Eifert & Forsyth, 2005).
5Prior to study training, therapists had received only one or two lectures on CBT and one lecture incorporating thirdwave behavioral
therapies at the point of initial study involvement.
J Consult Clin Psychol. Author manuscript; available in PMC 2016 January 19.
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= 6.82, SD = 1.60 (range 4–9) for a total of 75 Ps. The mean patient number for therapists
treating in both conditions was significantly higher than the mean for ACT- or CBT-only
therapists, ps < .001, pη2= .77 for each comparison; there were no differences between
ACT- and CBT-only therapists. This is because therapists were allowed to gain training in
the second treatment modality (e.g., in CBT if they started out in ACT) only if they had seen
at least several patients in their original modality (e.g., in ACT). Consequently, therapists
who treated in both conditions treated more overall Ps. We tested the possibility, therefore,
that therapists treating in different conditions evidenced systematic differences in
competency that impacted study findings, see Results, below.

Author Manuscript

Weekly, hour-long group supervision for study therapists was led separately by the principal
authors of the treatment manuals and by advanced therapists from UCLA and from Dr.
Hayes’ laboratory at the University of Nevada, Reno, where ACT was originally developed.
All sessions were videotaped for supervision purposes with a hidden video camera; sessions
were also audiotaped for therapy adherence purposes with a discrete digital recorder. Videos
were generally played in supervision sessions or watched beforehand by supervisors. ACT
supervision occurred by phone and Skype with offsite supervisors supplemented by
occasional face-to-face sessions whereas CBT supervision was face-to-face. All therapists
completed extensive training including an intensive 3-day workshop with the principal
treatment manual author (author M.G.C. for CBT, and author G.E. or Dr. Hayes for ACT)
prior to treating Ps. ACT and CBT manuals were matched on the number of sessions
devoted to exposure but differed in coping skills and the framing of the intent of exposure.

Author Manuscript

Cognitive Behavioral Therapy (CBT): CBT for anxiety disorders followed a protocol
authored by Craske (2005), which involved a single manual with branching mechanisms that
listed cognitive restructuring and behavioral exposure content for each anxiety disorder.
Session 1 focused on assessment, self-monitoring, and psychoeducation. Sessions 2–4
emphasized cognitive restructuring with hypothesis testing, self-monitoring, and breathing
retraining. Exposure (e.g., interoceptive, in-vivo, and imaginal) was tailored to the principal
diagnosis and focused on empiricism and anxiety reduction over time was introduced in
Session 5, and emphasized strongly in Sessions 6–11. Session 12 focused on relapse
prevention.

Author Manuscript

Acceptance and Commitment Therapy (ACT): ACT for anxiety disorders followed a
manual authored by Eifert and Forsyth (2005). Session 1 focused on psychoeducation,
experiential exercises and discussion that introduced acceptance, creative hopelessness, and
valued action. Creative hopelessness involved a process of exploring whether efforts to
manage and control anxiety had “worked” and experiencing how such efforts had led to the
reduction or elimination of valued life activities. Ps were encouraged to behave in ways that
enacted their personal values (“valued action”), rather than spend time managing anxiety.
Acceptance was explored as an alternative to controlling anxiety. Sessions 2–3 further
explored creative hopelessness and acceptance. Sessions 4 and 5 emphasized mindfulness,
acceptance and cognitive defusion, or the process of experiencing anxiety-related language
(e.g., thoughts, self-talk, etc.) as part of the broader, ongoing stream of present experience
rather than getting stuck in responding to its literal meaning. Sessions 6–11 continued to

J Consult Clin Psychol. Author manuscript; available in PMC 2016 January 19.
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hone acceptance, mindfulness, and defusion, and added values exploration and clarification
with the goal of increasing willingness to pursue valued life activities. Behavioral exposures,
including interoceptive, in-vivo, and imaginal, were employed as needed to provide
opportunities to practice making room for, mindfully observing, and accepting anxiety (all
types of exposure) and to practice engaging in valued activities while experiencing anxiety
(in-vivo exposures). Session 12 reviewed what worked and how to continue moving
forward. See supplementary materials for additional details.

Author Manuscript

Outcome measures—Because CBT emphasized symptom reduction whereas ACT
emphasized broader aims of psychological flexibility and valued living, we investigated two
sets of primary outcomes across both treatments: anxiety specific (i.e., symptom reduction
related) and non-anxiety specific, or broader outcomes. For the anxiety-specific measures,
we included the severity of each principal disorder. In addition, the mixed anxiety disorder
nature of our sample required utilization of anxiety-specific outcome measures that were
relevant across the anxiety disorders. We selected measures of worry, fear, and behavioral
avoidance, features that characterize all anxiety disorders (Craske et al., 2009), and
empirically tested them to ensure that they changed following treatment across the entire
sample (not merely within a single disorder). For the non-anxiety specific, broader measures
we assessed quality of life and psychological flexibility.
Anxiety-Specific Primary Outcomes

Author Manuscript

Diagnostic Interview Assessment: Clinical diagnoses were ascertained using the Anxiety
Disorders Interview Schedule-IV (ADIS-IV) (Brown, DiNardo, & Barlow, 1994). Doctoral
students in clinical psychology or research assistants served as interviewers after completing
15–20 hours of training and demonstrating adequate diagnostic reliability on 3 consecutive
interviews. ‘Clinical severity ratings’ (CSR) were made for each disorder by group
consensus on a 0 to 8 scale (0=none, 8=extremely severe). Ratings of “4” or higher indicated
clinical significance based on symptom severity, distress and disablement, and served as the
cutoff for study eligibility (see Craske et al., 2007). ADIS-IV interviews were audiorecorded and 15% (n = 22) were randomly selected for blind rating by a second interviewer.
6 Inter-rater reliability on the principal diagnosis was 100%. Inter-rater agreement on
dimensional CSR ratings was .65 with a single-measure, one-way mixed intraclass
correlation7 coefficient across the anxiety disorders. Inter-rater agreement for each specific
disorder (met DSM-IV criteria vs. subclinical vs. none) was as follows: SAD (10 subclinical
or clinical cases) and OCD (3 cases) ICC = 1.00 (100% agreement), PD/A (11 cases) ICC
= .91, GAD (8 cases) ICC = .85, and SP (7 cases) ICC = .75.

Author Manuscript

The Anxiety Sensitivity Index (ASI; Peterson & Reiss, 1992; Reiss, Peterson, Gursky, &
McNally, 1986)8 assesses fear of anxiety-related sensations (e.g. shortness of breath) based
on the belief that such sensations are harmful. Although particularly elevated in panic

6Given the mixed anxiety disorder sample and subsequently low n per disorder, ICCs for individual disorders should be interpreted
cautiously. Note, however, that agreement was based on all 22 rated audiotapes, not just the audiotapes of Ps with clinically significant
symptoms.
7This test was selected because the second interviewers included several different trained assessors who rated several tapes each.
8We used the original ASI because the revised ASI-3 (Taylor et al., 2007) was not yet published at study initiation.
J Consult Clin Psychol. Author manuscript; available in PMC 2016 January 19.
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disorder (Taylor, Koch, & McNally, 1992), the ASI shows elevation across most anxiety
disorders (Rapee, Brown, Antony, & Barlow, 1992) relative to nonanxious controls
(Peterson & Reiss, 1992). Current sample α’s = .85 (Pre) and .93 (Post). The Penn State
Worry Questionnaire (PSWQ; Meyer, Miller, Metzger, & Borkovec, 1990) assesses
clinically relevant worry. Although particularly elevated in GAD, the PSWQ shows
elevations across all anxiety disorders relative to non-anxious controls (Brown, Antony, &
Barlow, 1992). Current sample αs = .90 (Pre) and .93 (Post). The Fear Questionnaire’s (FQ;
Marks & Mathews, 1979) Main Target Phobia Scale, a single-item avoidance rating for each
P’s “main phobia”, was used as the behavioral avoidance outcome.

Author Manuscript

Broader (Non-Anxiety Specific) Primary Outcomes—The Quality of Life Inventory
(QOLI; Frisch, 1994b) assesses values and life satisfaction across 16 broad life domains and
has good test-retest reliability and internal validity (Frisch et al., 2005). Current αs = .86
(Pre) and .84 (Post). The Acceptance and Action Questionnaire-16 (AAQ; Bond & Bunce,
2000; Hayes et al., 2004) assesses psychological flexibility (Bond et al., 2011). The AAQ-16
is a 16-item version of the 7- and 9-item AAQ that is hypothesized to be more sensitive to
clinical change (Hayes et al., 2004). Both one and two-factor solutions have been fit to the
16-item AAQ (Bond & Bunce, 2000, 2003). Herein, a one-factor scale was used, with higher
scores indicating greater psychological flexibility. Current αs were .78 (Pre) and .86 (Post).
See supplementary materials for additional psychometrics on primary outcomes.
Secondary Outcomes

Author Manuscript

Use of Additional Treatment: As a behavioral indication of the degree to which each
treatment met clients’ needs, we assessed Ps reported use of additional (non-study-related)
psychotherapy and psychotropic medication at Post-12m FU with questions on the ADISIV..At each assessment point, we compared groups on the portion of Ps who initiated new,
dropped (e.g., among Ps using therapy or medication at the previous assessment point), or
were using any form (e.g., either new or continued from the previous assessment) of nonstudy psychotherapy or psychotropic medication.
Generalization of Treatment Effects: Based on the ADIS interview, co-occurring mood
and anxiety disorders (with CSR of 4+) at Post-12mFU were analyzed as an index of the
generalization of treatment effects. We examined the number of co-occurring anxiety
disorders, the presence of co-occurring mood disorders, and the total number of cooccurring anxiety and mood disorders as indices of the generalization of treatment effects.

Author Manuscript

Treatment Credibility—Prior to the second therapy session, after the treatment rationale
had been fully described, Ps completed a six-item treatment credibility questionnaire
adapted from Borkovec and Nau (1972), see Supplementary materials. Total sample α = .94;
ACT α = .92 and CBT α = .95.
Treatment Adherence and Therapist competence—Treatment sessions were
audiotaped and 143 sessions from 91 participants (50 in CBT, 41 in ACT) were randomly
selected for treatment adherence and therapist competency ratings using the Drexel
University ACT/CT Therapist Adherence and Competence Rating Scale (DUACRS;

J Consult Clin Psychol. Author manuscript; available in PMC 2016 January 19.
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McGrath, Forman, & Herbert, in preparation). The treatment adherence items (n = 49)
included 5 scales: general therapy adherence (12 items), general behavioral therapy
adherence (11 items), cognitive therapy adherence (10 items), ACT adherence (16 items)
and a therapist competence (5 items), see Supplementary materials. The first author of the
DUACRS (McGrath), who had no involvement with the current study and extensive training
in both ACT and CBT, completed adherence ratings. To check treatment integrity, the blind
rater (McGrath) noted which of 49 therapist adherence items (e.g., specific therapist
behaviors or therapy content) occurred in each 5-minute segment of therapy. Treatmentspecific subscale scores (indicating adherence to ACT or CBT) were calculated by dividing
the number of segments during which subscale-specific therapist behavior was present (i.e.,
at least one of the items composing a subscale was coded for that five-minute segment) by
the total number of segments in the session, yielding an estimate of the percentage of time
spent by the therapist on treatment-specific behavior. The general therapy adherence and
general behavioral therapy adherence scales were computed in similar manner. At the end of
each recording, therapist competence was rated and the mean of the scale items represented
the therapist competency rating for that session.
Statistical analyses—Raw data were inspected graphically; outliers (3SD) were replaced
with the next higher value, following the Winsor method (Guttman, 1973), prior to data
analysis. In full HLM models (see below), Level 1 and 2 residuals were examined for model
outliers and fit, and outliers (3SD) were treated in the Winsor method and on two occasions,
eliminated due to particularly strong and uncorrectable influence. Less than 5% of the data
were modified or eliminated during outlier correction.

Author Manuscript
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Longitudinal data were analyzed with hierarchical linear modeling (HLM) and hierarchical
multiple linear modeling (HMLM) in HLM 6.0 (Raudenbush, Bryk, & Congdon, 2004).
HLM/HMLM random effects models examined within and between group change across
time (pre, post, 6m FU, 12m FU) and by condition (ACT and CBT). HLM/HMLM
incorporates Ps with missing data by estimating the best fitting model from the data
available for each P (Hedeker & Gibbons, 2006). Therefore, for the intent-to-treat (ITT)
analyses, all data points for Ps who entered treatment were entered into the model. For
Completer results, which are reported when different from ITT results, analyses included Ps
who completed treatment and at least one subsequent assessment (Post, 6mFU, 12mFU). In
fitting models to the longitudinal data, different variance-covariance structures were
assessed starting with the simplest, the HLM compound symmetry model. HLM model fit
was compared with multiple HMLM level 1 variance-covariance options (homogenous,
heterogeneous, first order autoregressive, unstructured) using restricted log likelihood values
(−2LL) in chi-square comparisons (see Raudenbush, Bryk, Cheong, & Congdon, 2004). The
model with the best fit was selected; if models were not significantly different, the model
with the fewest parameters was selected.
In the HLM/HMLM models, assessment time points (Pre, Post, 6mFU, 12mFU) were
entered on Level 1, and nested within individuals on Level 2. Demographic and clinical
covariates, and Group (dummy coded ACT vs. CBT) were entered on Level 2. Betweengroup differences focused on group differences in change slopes over time and at Post and
12mFU time points. Due to curvilinear patterns over time, quadratic and cubic time terms
J Consult Clin Psychol. Author manuscript; available in PMC 2016 January 19.
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were tested on Level 1 and kept in final models if they were significant and significantly
reduced model deviance (−2LL) according to chi-square based model comparisons. Cubic
terms were fixed in order to not overestimate the model’s random effects. For analyses of
non-CSR outcomes, pre-CSR was covaried on the intercept to account for pre-treatment
diagnostic severity. Effect sizes for within-group change at each assessment point were
examined in models that included linear and quadratic slopes only for the sake of clarity and
brevity and to avoid overinflating within-group linear effect sizes, which can occur when
both quadratic and cubic terms are in the model. We computed d effect sizes that accounted
for the number of repeated measurement points as needed (Feingold, 2009)9 and used
Cohen’s (1988) guidelines for interpretation.

Author Manuscript

Differences in rate of improvement should translate into different outcomes at posttreatment or follow up. Therefore, the Post and 12mFU time points represented our main
time points of interest for examining cross sectional group differences.
For comorbidity analyses, we compared groups at Pre using chi-square and over time using
repeated measures GHLM random effects repeated measure models (see Raudenbush, Bryk,
Cheong, et al., 2004), which utilize Ps with incomplete data.

Author Manuscript

Three separate indices examined treatment response in terms of the percent of responders at
each assessment point (Post, 6mFU, 12mFU); chi-square analyses examined between group
differences. Diagnostic status improvement was defined in accordance with recent clinical
trials (Newman et al., 2011; Roemer et al., 2008) as a principal diagnosis CSR of 3 or
below. Reliable change was computed using the Jacobson & Truax (1991) method, using the
more conservative denominator recommended by Maassen (2004). To remain consistent
with previous randomized clinical trials, we focused the response indices on anxiety-specific
outcomes. Due to the range of principal disorders and conservative method of defining
change, we examined group differences in reliable change on at least 2/4 anxiety-specific
primary outcomes (reliable change status), as well as reliable change plus falling within 1
SD of the nonclinical normative range (or 3 or less on CSR) on at least 2/4 anxiety-specific
primary outcomes (high end state functioning status), and reliable change on the principal
disorder CSR plus CSR of 3 or below (diagnostic change status) (e.g., Newman et al., 2011;
Roemer et al., 2008). See supplementary materials for employed norms and computations
details, and Table 6 for reliable change critical values.

Author Manuscript

To assess if data were missing at random, we conducted chi-square comparisons on primary
outcomes comparing Ps who dropped out vs. finished treatment, and treatment finishers with
complete vs. incomplete data at 6mFU and 12mFU. For dropouts vs. finishers, no significant
differences emerged at Pre on any primary outcome variable. For treatment finishers with
complete vs. incomplete data, no significant differences emerged at Pre or Post, with the
minor exception that Ps with incomplete FU data had higher ASI scores at Pre (p = .04, pη2
=.05) but not at Post. The findings suggest that the data were missing at random.

9We did not report 95% confidence intervals for our Feingold (2009) effect sizes because there is not yet a method for doing so (see
Feingold, 2009; Odgaard & Fowler, 2010).
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Power analyses, conducted in Optimal Design (see Raudenbush & Liu, 2000), indicated that
to reach 80% power, a cross sectional between-group difference (e.g., at 12mFU) with an
effect size of .70 required 67 total Ps, whereas a between-group effect size of .50 required
126 total Ps. Therefore, our total sample size (n = 128) was sufficient to detect between
group differences of moderate size at each assessment point.

RESULTS
Pre-treatment Group Differences

Author Manuscript

At pre-treatment, ACT and CBT evidenced no significant differences on anxiety specific or
broader outcome measures, although ASI differences approached significance, t(111) =
1.91, p = .058 (all other outcome ps > .2). Further, ACT (8.82%, 3/34) and CBT (9.68%,
3/31)10 showed no differences in use of non-study psychotherapy at Pre, χ2 = .01, p = .91,
nor in use of psychotropic medication, see Table 1. ACT and CBT showed no significant
differences on socio-demographic or clinical characteristics in Table 1 with one exception.
Despite randomization procedures, there was a trend for higher rates of a principal diagnosis
of PD/A in CBT (49.3%) than in ACT (32.1%), χ2 = 3.79, p = .052. In HLM analyses,
principal PD/A diagnosis predicted superior CSR outcomes compared to non-PD/A
principal diagnoses, at Post (B = −1.14, SE = .45, t(126) = −2.53, p = .01, d = 1.31) and
6mFU (B = −1.01, SE = .51, t(126) = −2.11, p = .04, d = 1.16), but not at 12mFU (B = −.62,
p = .26). Despite the significant impact of PD/A on CSR outcomes, we did not covary PD/A
in further HLM/HMLM analyses to avoid further stratification of Ps into additional
subgroups that lacked apriori significance and to avoid reduced statistical power to examine
our principal comparison of CBT versus ACT. Principal PD/A did not predict other primary
outcomes for which we found significant CBT versus ACT differences.

Author Manuscript

Treatment Credibility
Treatment credibility scores (immediately prior to Session 2) differed significantly by
Group, F(1, 76) = 9.08, p= .004, pη2 = .11, with CBT evidencing higher scores (M = 6.08,
SD = 1.44, n = 51) than ACT (M = 4.92, SD = 1.91, n = 27). Missing treatment credibility
data from the first 24 ACT participants11 resulted in a lower n in this group. When the first
24 CBT participants were excluded from analyses, group differences held: F(1, 62) = 6.34, p
= .01, pη2=.09, with CBT again showing significantly higher scores (M = 6.00, SD = 1.53, n
= 37) than ACT (M = 4.92, SD = 1.91, n = 27).
Therapist competence and Treatment Integrity

Author Manuscript

Therapist competency scale scores (e.g., “knowledge of treatment”, “skill in delivering
treatment”, and “relationship with client”; 1=poor, 3=good, 5=excellent) indicated “good”
therapist skills in CBT (M = 3.08, SD = .64) and ACT (M = 3.25, SD = .77). ACT therapists

10To comply with IRB requirements, the original ADISs were already shred for the remaining half of the sample by the point at which
we extracted these data. There is no reason to believe, however, that the remaining half differed from the first half in use of non-study
psychotherapy.
11Due to administrative error in which it was not understood that the treatment credibility measure should be administered to both the
CBT and ACT Ps.
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and CBT therapists did not significantly differ on competency ratings F(1,77) = 1.17, p = .
28, pη2 = .02.

Author Manuscript

Cognitive therapy adherence scores were higher for CBT (M=62.23, SD = 18.07) than ACT
(M = 5.03, SD = 9.83), F(1, 87) = 316.88, p < .001, pη2 = .76. Conversely, ACT adherence
scores were higher for ACT (M = 82.26, SD = 18.04) than CBT (M = 3.94, SD = 6.40), F(1,
87) = 813.58, p < .001, pη2 = .90. On the behavioral adherence scale, CBT (M = 47.41, SD =
23.59) scored significantly higher than ACT (M = 25.35, SD = 18.83), F(1, 87) = 22.77, p
< .001, pη2 = .21, however, this scale included a range of behavioral items such as therapist
modeling that are more commonly used in CBT. We explored group differences on
behavioral exposure-related items from the behavioral adherence scale; differences between
CBT (M = 14.25, SD = 18.34) and ACT (M = 8.01, SD = 11.77) on behavioral exposure
items, p = .07 pη2 = .04 did not reach full significance. The general therapy adherence scale
did not differ significantly between CBT (M = 96.89, SD = 9.86) and ACT (M = 99.10, SD =
4.27), F(1, 87) = 1.72, p = .19, pη2 = .02. The combined results show that therapists
exhibited strong adherence to their assigned treatment.

Author Manuscript

To test the possibility that therapists treating in different conditions varied in competence,
we compared CBT-only, ACT-only, and both-type (e.g., treated Ps in both CBT and ACT)
therapists on competence. CBT-only (M = 2.96, SD = .64) and ACT-only therapists (M =
3.02, SD = .62) showed no differences in competence (p = .81), nor did ACT-only and bothtype therapists (p = .13). Both-type therapists, however, showed significantly higher
competence (M = 3.36, SD = .72) than CBT-only therapists (M = 2.96, SD = .64), F (1, 73) =
5.18, p = .03, pη2 = .07. To determine if therapists who treated in a single condition
impacted study findings, we reran the CSR analyses twice, once without CBT-only
therapists and once without CBT- and ACT-only therapists. Although reduced power from
lower n (which meant the analyses fell below the 80% statistical power level) meant that
group differences were not statistically significant, the pattern of findings for group
differences matched those reported for the full sample below, suggesting that therapist
assignment did not impact study findings. See supplementary materials for an example of
these results.
Treatment Attrition

Author Manuscript

Eighty-five of 128 Ps (66%) completed the full 12 sessions of therapy, including 68%
(48/71) in CBT and 65% (37/57) in ACT. The additional 43 Ps (34%) received a partial dose
of therapy: 13 Ps attended 1 session (5 ACT, 8 CBT) and 30 Ps (15 in each ACT and CBT)
attended 2 to 11 therapy sessions. The portion of Ps who did not complete the full 12
sessions did not differ by Group, χ2(1)= .40, n.s. Finally, the total number of treatment
sessions attended by the ITT sample did not differ by Group; CBT M = 9.62 (SD = 4.08),
ACT M = 9.37 (SD = 4.05), F(1, 126) = .12, p = .73, pη2 = .00.
Primary Outcomes
Table 2 provides the means and SDs for primary outcomes at each assessment point. We
conducted separate ITT and treatment completer analyses. Completer analyses are reported
when they differ in significance or effect size from the ITT analyses. Effect sizes for within-
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group and between-group change are listed by group in Table 3. Table 4 provides the means,
SDs, effect sizes, and diagnostic response rates for primary outcomes at Post for each
anxiety disorder. Individual disorder outcomes were not analyzed or discussed further,
however, because we did not design or power this study to examine group differences in
outcomes for individual anxiety disorders.
Primary Outcomes Change Slopes: ITT

Author Manuscript

Anxiety Specific Outcomes: With the intercept (0) representing Pre, the HLM ITT model
for CSR outcomes showed significant effects of linear, quadratic and cubic change over
Time, all ps <.001, but no significant Group × Time interactions. However, after treatment,
the groups showed significant differences in CSR linear slope (within the full model
accounting for Group on higher order change terms) such that ACT continued to improve
from Post to 12mFU, whereas CBT maintained but did not continue to improve as much, B
= .58, SE = .28, t(126) = 2.03, p = .04, d = 1.33 (effect size of group difference from Post to
12mFU), see Figure 2a. The CSR slopes after treatment were best fit within a HMLM
unrestricted covariance model.
The HLM ITT model for ASI, PSWQ, and FQ outcomes showed significant effects of
linear, quadratic, and cubic change over Time, all ps <.01, but no significant Group × Time
interactions from pre- to post-treatment, or after treatment.
Broader Outcomes: The HLM ITT models for AAQ and QOLI outcomes showed
significant effects of linear, quadratic, and cubic change over Time, all ps ≤ .001, but no
significant Group × Time interactions from pre- to post-treatment, or after treatment.

Author Manuscript

Primary Outcomes Change Slopes: Completers
Anxiety Specific Outcomes: Completers evidenced a similar but smaller Group × Linear
slope interaction for CSR after treatment, B = .43, SE = .21, t(77) = 2.05, p = .04, d = .90,
favoring ACT. A HMLM homogenous covariance structure best fit the data.
Primary Outcomes at Post: ITT Sample
Anxiety Specific and Broader Outcomes: At Post, ACT and CBT did not differ
significantly on any anxiety specific measure or broader outcome measure.
Primary Outcomes at 12mFU: ITT Sample
Anxiety Specific Outcomes: At 12mFU, ACT and CBT did not differ on any anxiety
specific measure.

Author Manuscript

Broader Outcomes: At 12mFU, CBT demonstrated higher QOLI ratings than ACT, B = .
83, SE = .41, t(113) 2.05, p = .04, d = .43, see Figure 2b. In addition, group differences in
AAQ approached significance, B = 5.10, SE = 2.86, t(117) = 1.78, p = .08, d = .42, with
ACT showing greater psychological flexibility than CBT, see Figure 2c. An HLM
covariance structure was the best fit for 12mFU outcomes.

J Consult Clin Psychol. Author manuscript; available in PMC 2016 January 19.

Arch et al.

Page 14

Primary Outcomes at 12mFU: Completer Sample
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Anxiety Specific Outcomes: ACT was assigned significantly lower CSR ratings for the
principal anxiety disorder than CBT, B = 1.01, SE = .49, t(83) = 2.04, p = .04, d = 1.0512. A
homogenous level 1 variance HMLM model best fit the CSR data. At this assessment point
(12mFU), PD/A status was unrelated to CSR outcomes (see Results, above), bolstering the
significance of this finding. The groups did not differ significantly on the ASI, PSWQ or
FQ.
Broader Outcomes: CBT showed higher QOLI values than ACT, B = .68, SE = .32, t(65) =
2.12, p = .03, d = .36. ACT showed significantly higher AAQ scores than CBT, B = 6.76, SE
= 2.65, t(66) = 2.65, p = .01, d = .59.
Secondary Outcomes

Author Manuscript

Use of Additional Psychotherapy and Medication: There were no group differences at
Post, 6mFU or 12mFU in use of new or any (e.g., new or continued) psychotropic
medication, all ps > .44, see Supplementary materials. For dropped medication, there was no
group difference at 6mFU, p > .69, with n’s at 12mFU too small to compare. At Post,
however, CBT resulted in borderline greater dropped medication than ACT, B = 2.13, SE =
1.10, p = .05 (p = .053), Exp(B) = 8.42 (95% CI: .97 to 73.06), with 37.04% (10/27) of CBT
versus 7.14% (1/14) of ACT Ps dropping medication from Pre to Post. Because there were
no group differences in overall medication use at Post (p = .86), however, we did not further
analyze this borderline significant finding.

Author Manuscript

The groups did not differ in new, dropped, or any outside psychotherapy use at either Post or
12mFU, ps > .26. At 6mFU, groups did not differ on new (p = .13) psychotherapy, however,
ACT reported greater use of any psychotherapy (e.g., new or continued) than CBT, B = 1.29,
SE = .63, Wald (1) = 4.28, p = .04, Exp(B) = 3.65 (95% CI: 1.07 to 12.42): 39% (11/28) of
ACT Ps versus 19% (5/27) of CBT Ps. To explore the clinical impact of this finding, we
reran the CSR analyses dropping the Ps who reported any psychotherapy use at 6mFU, and
found that the results followed the same pattern as the ITT analysis reported above. Further,
we assessed whether psychotherapy use at 6mFU predicted principal diagnosis CSRs at
6mFU or 12mFU and found that it did not (ps > .4 for both ACT and CBT). Given these two
sets of null findings, additional psychotherapy at 6mFU was not covaried in subsequent
analyses. Exploratory analyses showed, however, that ACT patients who remained severe
(CSR 4+) following treatment were somewhat more likely to seek additional treatment than
CBT patients that remained severe, p = .07, see Supplementary materials.

Author Manuscript

Generalization of Treatment Effects: The groups did not differ significantly in the number
of co-occurring anxiety, mood, or anxiety and mood disorders combined at Pre, ps >. 18.
Nor did the groups differ significantly in rates of reduction of co-occurring disorders over

12Due to the fact that study selection criteria required a CSR of 4 or above, the pre-treatment CSR range was restricted. Thus, the pretreatment SD, which serves as the denominator in the Feingold (2009) effect size formula, was less than half the SD of the 12m FU
CSRs in magnitude (whereas 12m FU SDs on other outcome measures were ≤ their SDs at pre-treatment). If we use the SD at 12m FU
to compute effect size for 12m FU group differences on CSR, d = .44.
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Time, with both groups showing decreases in co-occurring disorders following treatment,
see Table 5.
Treatment Response Rates—The groups did not significantly differ in treatment
response rates, see Table 6.

DISCUSSION

Author Manuscript

Within a randomized clinical trial, we aimed to test the efficacy of ACT relative to a gold
standard treatment for anxiety disorders, CBT. Because ACT represents a transdiagnostic
treatment approach (Hayes et al., 1999), we focused on a mixed anxiety disorder sample.
We explored the degree to which each treatment reduced anxiety symptoms, and tested the
hypothesis that ACT would improve measures of quality of life and psychological flexibility
to a greater extent than CBT.
Overall, the findings demonstrated that ACT and CBT did not differ significantly at posttreatment on either anxiety specific or broader outcomes. Over the follow up interval, group
differences emerged with ACT showing superiority over CBT on principal disorder severity
and psychological flexibility outcomes. However, the follow-up group differences are
complicated by the fact that significantly more ACT participants utilized outside
psychotherapy during the initial followup interval than CBT participants. Our hypothesis
that ACT would improve more than CBT on broader outcomes met with limited support; on
one broad outcome, ACT improved more than CBT but on the other, CBT improved more
than ACT.
Primary Outcomes

Author Manuscript
Author Manuscript

On all primary outcomes, ACT and CBT showed substantial improvement from pre- to posttreatment. On anxiety-specific outcomes, within-group linear effect sizes in ACT and CBT
from pre- to post-treatment ranged from very large for principal disorder severity (CSR) to
moderate or large for other anxiety outcomes. Thus, both treatments were highly efficacious.
Anxiety-related outcomes continued to improve through the six-month follow-up assessment
within both ACT and CBT. From six to twelve months, improvement slowed but treatment
gains endured. On broader outcomes, both groups showed large improvements in
psychological flexibility and more moderate improvements in quality of life at posttreatment. Broader outcomes continue to improve through six-month follow up and gains
endured from six to twelve-month follow up. In summary, ACT and CBT resulted in
significant improvements from pre- to post-treatment that were maintained or improved
upon during follow up, on both anxiety-specific and broader outcomes. Further,
improvements were evident across two different dimensions of treatment response, namely,
more objective, clinician-rated CSR outcomes as well as subjective, patient-rated self-report
outcomes.
From the end of treatment through to the 12-month follow up, several noteworthy group
differences emerged. On anxiety-specific outcomes, ACT demonstrated a steeper
improvement rate than CBT in the principal disorder severity rating, a difference of large
effect size. ACT’s steeper improvement rates resulted in lower principal disorder severity
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ratings than CBT at the 12 month follow up, again of large effect size, although statistically
significant effects were limited to the Completer sample. Over the long term, therefore, ACT
more effectively reduced principal anxiety disorder severity than CBT among those who
completed treatment. This finding is consistent with a previous study (Lappalainen et al.,
2007) that found that ACT resulted in more symptom improvement that CBT, albeit in a
much smaller sample (n = 28) of unselected outpatients. However, since more ACT than
CBT patients in the current study utilized outside therapy during the initial follow up
interval, we cannot fully determine whether ACT’s superiority resulted from the ACT
treatment alone or ACT plus additional psychotherapy. Excluding patients using non-study
therapy from the principal disorder severity analyses, however, did not change the pattern of
results, suggesting that use of non-study therapy did not influence the principal disorder
severity findings.

Author Manuscript

For broader outcomes, one unexpected finding was that CBT participants reported
significantly higher quality of life than ACT at 12-month follow up, a difference of
moderate effect size. It had been hypothesized that the explicit focus on valued living in
ACT would lead to greater improvements in quality of life. Conceivably, our measure of
quality of life was too general to capture values-specific improvements. Consistent with
hypotheses, however, ACT participants reported higher levels of psychological flexibility
than CBT at 12-month follow up on a measure specifically designed to capture ACT-related
improvement (Hayes et al., 2004). Please refer to the Supplementary materials for further
discussion of primary outcomes.

Author Manuscript

Finally, ACT and CBT produced similar rates of reliable change, diagnostic improvement,
and high end state functioning, comparable to our recent review showing that on average the
mean response rate for CBT across anxiety disorder studies from 2000–2011 was 51.36% at
post-treatment (180 studies) and 54.80% at follow-up (71 studies) (Loerinc, Meuret,
Twohig, Rosenfield, & Craske, in submission). Very few studies (of the 180) used reliable
change index methods to compute treatment response rates but the few that did (e.g., Addis
et al., 2004; Carter, Sbrocco, Gore, Marin, & Lewis, 2003) evidenced response rates
comparable to those in the present study.
Secondary outcomes

Author Manuscript

As noted above, more ACT than CBT patients reported non-study psychotherapy (new or
continued psychotherapy) at the 6-month follow-up assessment, although there were no
group differences in the initiation of new psychotherapy during this period nor in medication
use, nor any group differences on these variables at 12-month follow up. Reasons for this
group difference, nonetheless, were explored. The data showed some support for the notion
that ACT patients who remained distressed following treatment were more likely to seek
additional psychotherapy than CBT patients who remained distressed. Another possibility is
that the broader focus on exploring personal values, pursuing meaningful life behaviors, and
contacting the full range of emotions in ACT inspired patients to continue engaging in
psychotherapy.
Both ACT and CBT resulted in robust reductions in co-occurring mood and anxiety
disorders. This finding demonstrates that treatment effects generalized in both groups,
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replicating and extending previous work on the broader effects of CBT for panic disorder
and generalized anxiety disorder (e.g., Borkovec, Abel, & Newman, 1995; Tsao,
Mystkowski, Zucker, & Craske, 2005).
Treatment and Therapist Variables

Author Manuscript

Attrition rates were relatively high across both ACT and CBT; however, no group
differences emerged. Attrition was comparable to some large trials of CBT for anxiety
disorders (e.g. Barlow et al., 2000) but was higher than the mean attrition (23%) reported in
a meta-analysis of CBT studies for anxiety disorders (Hofmann & Smits, 2008). Although
attrition reasons for many patients remain unknown, we suspect that four features of our
study may have contributed to attrition. First, the study took place in a difficult to locate,
high-traffic, parking-challenged clinic with limited public transportation options, and travel
times to and from treatment often exceeded 45 minutes each way. Second, our assessments
included a 2 to 3 hour physiological laboratory session that was strongly anxiety provoking
for many patients (e.g. involving hyperventilation, negative picture slide viewing, etc.),
which may have discouraged patients from study completion. Third, unlike many studies
where treatment is free or low cost for all, most patients paid for treatment, and incurred
significant parking costs. Fourth, we offered few incentives for treatment completion and
failed to sufficiently incentivize post-treatment and follow-up assessment completion.
Higher incentives may have been particularly needed in a study with such significant
treatment barriers (e.g., long travel times, parking fees and difficulties, treatment fees, etc.).

Author Manuscript

An important finding to emerge from blind treatment integrity ratings was that ACT and
CBT were clearly distinguished from one another and that therapists strongly adhered to the
designated treatment. Despite the use of novice student therapists, therapists averaged
“good” overall skills across both treatments with no differences between treatment groups.
Therapists treating patients in both CBT and ACT nonetheless evidenced significantly
higher competence than therapists treating in CBT only. Principal diagnostic severity
analyses of patients treated only by “both-type” therapists showed the same pattern of
outcomes, however, suggesting that these differences did not impact overall study findings.

Author Manuscript

Early in treatment, CBT was rated as a more credible treatment than ACT by a medium
effect size. Thus, ACT therapists were not as successful as CBT therapists in convincing
patients early on that they offered a credible treatment. This difference did not appear to
influence attrition rates, which did not differ by group. Conceivably, abstract ideas of
acceptance and creative hopelessness in initial ACT sessions (rather than concrete skills in
CBT) contributed to a diminished sense of treatment credibility. Future studies should assess
treatment credibility regularly throughout ACT to determine whether ACT follows a delayed
trajectory in convincing patients that it offers something credible, or whether ACT patients
remain skeptical throughout treatment but improve anyway. The latter would suggest that
treatment credibility is relatively unimportant to the success of ACT. Certainly, in the
current study, the lowered credibility ratings relative to CBT did not appear to disadvantage
ACT outcomes relative to CBT outcomes.
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Several study limitations should be noted. First, our mixed anxiety disorder sample limits
the conclusions that may be drawn about any single anxiety disorder. Anxiety disorders
typically co-occur at high rates with other anxiety disorders and share many common
features (see Barlow, 2002; Craske et al., 2009), however, strengthening the ecological
validity of this approach. Second, relatively high attrition rates may have resulted in
underestimated treatment effects or compromised ability to accurately assess treatmentrelated improvements in the ITT sample. On the other hand, we utilized a sophisticated
statistical approach (HLM, HMLM) that utilized patients with incomplete data and drew
upon all available data in the ITT analyses; we also conducted a separate Completers
analyses. Third, we did not assess therapist allegiance, which may have impacted treatment
results given that the study was conducted within a CBT-renowned research clinic. Based on
the relatively inexperienced and junior nature of the therapists, however, allegiance is
unlikely to be a significant factor. Therapist experience raises another limitation, which is
that the results may differ in the hands of more experienced therapists. Fourth, CBT
supervision was conducted onsite in a face-to-face manner whereas most ACT supervision
was conducted via phone or Skype with offsite supervisors. We did not assess supervision
quality and thus could not investigate the impact of this group difference. Fifth, we did not
systematically assess reasons for attrition, and thus could not assess whether ACT and CBT
differed in the extent to which patients dropped out because they were unsatisfied with
treatment. Future ACT/CBT studies should assess group differences in stated reasons for
attrition. Sixth, we utilized a single item rating from the Fear Questionnaire for behavioral
avoidance due to the lack of avoidance measures relevant to all anxiety disorders. Seventh,
we used a website to generate the randomization sequence whereas use of an external
agency would have been preferable. Eighth, we did not include a no-treatment or treatmentas-usual control group, which may have obscured our capacity to assess improvement due to
treatment versus the passage of time. It has been argued, however, that comparing a newer
to a well-established treatment does not require a no-treatment or waitlist control group and
is more ethical without one (Kazdin, 2002). Also, the roughly equal number of treatment
sessions devoted to behavioral exposure in ACT and CBT may have obscured treatment
differences. The two treatment conditions were matched on exposure, albeit framed with
different intents, given the potency of exposure as a change agent. This feature may have
altered the way that ACT is typically done. In addition, the Penn State Worry Questionnaire
scores at pre-treatment in the GAD subsample were considerably lower that those in recently
published randomized trials for GAD (Newman et al., 2011; Roemer et al., 2008), which
may hold implications for the interpretation of findings in this subgroup. Finally, regarding
the generalizability of our findings, our sample largely reflected the racial, ethnic, and sex
distribution of U.S. residents at the time of data collection (Bureau, 2012), supporting the
broad generalizability of our findings. On the other hand, our sample was relatively educated
(the average participant had completed 3.5 years of college) and thus, our findings may not
generalize to less educated samples. Further, we cannot assume that treatment was equally
efficacious across racial subgroups because we lacked the statistical power to examine
whether outcomes differed by race. This remains an important question for future research.
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Summary and conclusion
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To our knowledge, this study represents the first randomized clinical trial comparing ACT
and CBT for anxiety disorders. Despite differences in underlying treatment models, the
overall findings are characterized by similarities in the immediate and long-term impact of
both treatments. We have argued elsewhere (Arch & Craske, 2008) that ACT and CBT for
anxiety disorders may represent different approaches to affecting common therapeutic
changes. This study largely supports this hypothesis. On the other hand, some differences
did emerge, in that CBT resulted in higher quality of life whereas ACT resulted in greater
psychological flexibility, and, among those who completed treatment, lower principal
anxiety disorder severity, over the follow-up. Overall, our findings suggest that ACT is a
highly viable psychosocial treatment alternative to CBT, the current gold standard
psychosocial treatment for anxiety disorders. Further, they pave the way for future
investigations of for whom each treatment approach is most effective, and the shared versus
unique mechanisms of therapeutic change.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1.

Patient Flow
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Figure 2.

a–c. Primary outcomes in the ITT sample with ACT vs. CBT differences
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23.6%
(30/127)
5.62 (.92)

Principal disorder clinical severity rating (mean)

4.7%
(6/127)

Specific Phobia

Comorbid depressive disorderc

13.4%
(17/127)

Obsessive-compulsive disorder

33.1%
(42/127)

20.5%
(26/127)

Generalized anxiety disorder

Comorbid anxiety disorder (1+)c

19.7%
(25/127)

Social anxiety disorder

5.70 (.89)

23.2%
(13/56)

39.3%
(22/56)

3.6%
(2/56)

16.1%
(9/56)

25.0%
(14/56)

23.2%
(13/56)

Fisher’s exact test p value was reported due to small n.

c
Comorbidity was defined as a clinical severity rating of 4 or above on the ADIS

Demographic data was missing for 1 P.

b

d

5.55 (.94)

23.9%
(17/71)

28.2%
(20/71)

5.6%
(4/71)

11.3%
(8/71)

16.9%
(12/71)

16.9%
(12/71)

CBT
(n=71)

.94

.01

1.75

.62

1.26

.79

t value or
χ2

.35

.92

.19

.69d

.43

.26

.37

p

For race/ethnicity and marital status, analyses assessed group differences in minority versus white and married versus non-married status.

a
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Means and standard deviations for primary outcomes at each assessment point
Measure and condition

Pre-treatment
M (SD)

Post-treatment
M (SD)

6-month
M (SD)

12-month
M (SD)

ACT

5.70 (.89)

3.11 (2.21)

2.77 (2.39)

2.33 (1.98)

CBT

5.55 (.94)

2.90 (2.12)

2.67 (2.24)

2.94 (2.52)

ACT

31.81 (11.25)

18.65 (11.89)

14.56 (10.14)

17.05 (12.62)

CBT

27.60 (11.81)

18.68 (11.16)

20.47 (12.90)

15.64 (8.04)

ACT

46.52 (11.93)

39.89 (11.01)

37.79 (10.87)

39.32 (12.26)

CBT

45.00 (12.82)

37.63 (15.22)

37.72 (13.04)

37.14 (12.72)

ACT

5.84 (2.34)

4.13 (2.37)

4.00 (2.66)

4.28 (2.72)

CBT

5.34 (2.95)

4.06 (2.96)

4.22 (3.12)

3.82 (2.70)

ACT

.19 (1.85)

1.42 (1.88)

.50 (1.43)

1.17 (1.51)

CBT

.55 (2.10)

1.78 (1.35)

1.45 (1.52)

1.86 (1.88)

ACT

59.01 (12.35)

70.82 (13.14)

72.14 (10.86)

71.71 (11.42)

CBT

58.49 (11.84)

69.43 (14.75)

68.38 (13.76)

68.43 (11.65)

Anxiety-Specific Outcomes
Clinician’s Severity Rating

Anxiety Sensitivity Index

Author Manuscript

Penn State Worry Questionnaire

Fear Questionnaire (avoidance)

Broader Outcomes
Quality of Life Index

Author Manuscript

Acceptance and Action-16

Author Manuscript
J Consult Clin Psychol. Author manuscript; available in PMC 2016 January 19.

Author Manuscript

Author Manuscript

Author Manuscript
−1.98
−0.46

Linear 6–12m FU

−0.65
−0.12

Linear Post-FU

Linear 6–12m FU

−0.40
−0.06

Linear Post-FU

Linear 6–12m FU

−0.38
0.06

Linear Post-FU

Linear 6–12m FU

−0.02

−0.27

−0.52

−0.07

−0.36

−0.64

−0.15

−0.39

−0.63

−0.08

−1.78

−3.46

CBT
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0.63
0.10

Linear Post-FU

Linear 6–12m FU

0.00

0.45

0.90

0.21
0.00

Linear Post-FU

Linear 6–12m FU

0.12

0.26

0.43

0.12

0.06

0.00

0.10

0.18

0.26

Quadratic: effect size (d)

Quadratic: β

Quadratic: effect size (d)

Quadratic: β

Quadratic: effect size (d)

Quadratic: β

Quadratic: effect size (d)

Quadratic: β

Quadratic: effect size (d)

Quadratic: β

Quadratic: effect size (d)

Quadratic: β

−0.08

−0.15

−0.27

−3.20

0.13

0.34

0.17

2.00

0.26

3.08

0.82

0.71

ACT

−0.11

−0.21

−0.22

−2.70

0.22

0.61

0.14

1.64

0.12

1.39

0.84

0.73

CBT

Notes: For the sake of clarity, effect sizes reflect HLM models with linear and quadratic time terms only. Quadratic terms are invariant across assessment points.

0.43

Linear Pre-Post

QOLI (higher scores indicate improvement)

1.16

Linear Pre-Post

0.08

0.11

0.31

0.02

0.05

0.11

0.03

0.26

0.55

0.38

0.32

0.26

Between
Groups

AAQ (higher scores indicate improvement)

Non-Anxiety Specific

−0.83

Linear Pre-Post

FQ

−0.74

Linear Pre-Post

PSWQ

−1.18

Linear Pre-Post

ASI

−3.74

Linear Post-FU

ACT

Linear Pre-Post

CSR

Anxiety Specific

Outcomes:

Effect sizes (d) of Within and Between Subject Effects for Primary Outcomes

Author Manuscript
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CSR = ADIS-IV principal disorder clinical severity ratings; ASI = Anxiety Sensitivity Index; PSWQ = Penn State Worry Questionnaire; FQ = Main Target Phobia Scale (behavioral avoidance rating) from
the Fear Questionnaire; AAQ = Acceptance and Action Questionnaire; QOLI = Quality of Life Inventory
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5.57 (.88)

32.03 (9.57)

CBT (n = 33 Pre)

5.75 (1.14)

CBT (n = 12 Pre)

CBT (n = 10 Pre)
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5.25 (.97)

CBT (n = 12 Pre)

52.14 (10.34)

CBT (n = 11 Pre)

Obsessive Compulsive Disorder

50.50 (10.83)

ACT (n = 12 Pre)

Penn State Worry Questionnaire

6.07 (.73)

ACT (n = 14 Pre)

Clinician’s Severity Rating

Generalized Anxiety Disorder

17.45 (9.78)
20.60 (11.01)

ACT (n = 11 Pre)

FQ- Social Phobia Subscale

5.46 (.88)

ACT (n = 13 Pre)

Clinician’s Severity Rating

Social Anxiety Disorder

37.29 (6.73)

ACT (n = 17 Pre)

Anxiety Sensitivity Index

5.56 (.78)

CBT (n = 35 Pre)

Pre
M (SD)

ACT (n = 18 Pre)

Clinician’s Severity Rating

Panic disorder with or without Agoraphobia

Anxiety Disordera and Measure

42.43 (14.65)

35.26 (8.81)

3.00 (2.45)

1.80 (1.69)

14.67 (8.26)

16.63 (7.60)

3.56 (1.24)

4.33 (1.73)

17.63 (10.87)

25.56 (12.39)

2.22 (2.15)

2.40 (2.27)

Postb
M (SD)

37.20 (13.81)

35.17 (5.64)

0.00 (.00)

1.75 (2.19)

14.67 (6.67)

14.80 (9.68)

3.33 (1.32)

3.43 (2.07)

18.72 (8.96)

26.67 (12.42)

2.59 (2.45)

2.00 (2.74)

6mFUb
M (SD)

40.75 (12.09)

36.09 (17.64)

1.50 (3.00)

2.00 (1.55)

17.86 (6.96)

17.20 (9.52)

4.00 (2.00)

2.60 (2.07)

15.29 (8.88)

23.60 (14.12)

2.58 (2.84)

2.00 (2.08)

12mFUb
M (SD)

−.25

−.58

−2.97/.58

−5.70/1.47

−54/.16

−.56/.19

−.59

−.93

−1.31/.32

−.98/.19

−4.02/1.02

−4.24/.93

Linear/Quadratic d effect size for Pre-Postc
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36.69 (17.61)
40.60 (23.93)

ACT (n = 7 Pre)

CBT (n = 5 Pre)

27.25 (11.47)

37.50 (24.37)

5.00 (1.58)

4.00 (2.24)

35.00 (22.63)

28.25 (18.95)

4.50 (2.38)

4.00 (2.74)

28.00 (18.38)

26.98 (13.69)

3.50 (2.52)

2.00 (2.83)

12mFUb
M (SD)

−.25

−.07

−1.03/.15

−2.67/.52

Linear/Quadratic d effect size for Pre-Postc

For ease of comparison with full-sample data reported in Table 3, we employed the pooled SD from the entire sample as the denominator in the Feingold (2009) effect size magnitude formula. This
resulted in somewhat more conservative (lower) effect sizes for some measures.

These represent the mean and standard deviation for Ps with data at each assessment point.

b

c

5.88 (.84)

CBT (n = 8 Pre)

PI-WSUR

5.67 (1.23)

ACT (n = 9 Pre)

6mFUb
M (SD)

We did not compute separate means or standard deviations for specific phobia Ps because of their low numbers (n = 6).
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8.1%
(3/37)
18.9%
(7/37)

Mood Disorders

Mood or Anxiety

3.8%
(1/26)
11.5%
(3/26)

Mood Disorders

Mood or Anxiety

5.9%
(1/17)
5.9%
(1/17)
11.8%
(2/17)

Anxiety Disorders

Mood Disorders

Mood or Anxiety

12m FU

7.7%
(2/26)

Anxiety Disorders

6m FU

10.8%
(4/37)

Anxiety Disorders

p ≤ .001

p ≤ .01,

***

**

Within group

*

52.8%
(29/56)

Mood or Anxiety

Posttreatment

23.2%
(13/56)

39.3%
(22/56)

ACT

Mood Disorders

Anxiety Disorders

Pre-Treatment

% of Ps with co-occurring disorders

14.8%
(4/27)

7.4%
(2/27)

7.4%
(2/27)

5.6%
(2/36)

2.8%
(1/36)

5.6%
(2/36)

8.7%
(4/46)

2.2%
(1/46)

8.7%
(4/46)

41.2%
(28/68)

23.9%
(17/71)

28.2%
(20/71)

CBT

p=.77

p=.85

p=.85

p=.77

p=.85

p=.85

p=.17

p=.21

p =.75

p=.24

p=.92

p=.19

Between Group χ2

.47**
(CI: .29, .78)
.36**
(CI: .17, .76)
.44**
(CI: .26, .75)

.38***
(CI: .24, .59)
.43**
(CI: .23, .83)
.41***
(CI: .26, .63)

ACT: ∆ slope over time (odds ratio)1`
CBT: ∆ slope over time (odds ratio)
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Co-occurring disorders: Rates and improvement among Ps with data at each time point
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The odds ratios are based on fixed GHLM linear time slopes for within-group change over time for dichotomous outcomes, covarying pre-treatment CSR for the principal diagnosis at the model’s
intercept. They are reported here at post-treatment but characterize the linear change rate over the pre-treatment to 12m FU period.
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44.4% (16/36)
53.6% (15/28)
52.2% (12/23)

Post-treatment

6-month

12-month

52.6% (10/19)

47.1% (8/17)

56.7% (17/30)

ACT

.00

.09

.98

χ2
p

.98

.76
.01

.05

.12

Cramer’s v

53.6% (15/28)
39.1% (9/23)

6-month

12-month

47.4% (9/19)

47.1% (8/17)

50.0% (15/30)

ACT

.29

.18

.05

χ2

.59

.67

.82

p

59.5% (22/37)
50.0% (16/32)

6-month

12-month

54.5% (12/22)

44.4% (12/27)

44.7% (17/38)

ACT

.11

1.41

.34

χ2

.74

.24

.56

p

.05

.15

.06

Cramer’s v

1
Reliable change required the following minimum improvement values from pre-treatment (see Supplementary Materials for computational details): principal disorder clinical severity rating (CSR) = 2.75,
Penn State Worry Questionnaire = 10.03, Anxiety Sensitivity Index = 10.48, Fear Questionnaire Main Target Phobia Avoidance Rating = 1.97.

51.0% (25/49)

CBT

Post-treatment

Assessment

.08

.06

.03

Cramer’s v

Shows reliable CSR change1 and Does not meet clinical diagnostic criteria (CSR ≤ 3)

47.2% (17/36)

CBT

Post-treatment

Assessment

Shows reliable change1 and High endstate functioning based on 2 of 4 anxiety-specific outcomes

CBT

Assessment
.32
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Shows reliable change1 on at least 2 of 4 anxiety-specific outcomes
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Response Rates on Treatment Response Indices
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